Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation
NCT05555641
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Critical Illness
Anticoagulation
Interventions
DRUG:
Nafamostat Mesylate
DRUG:
Unfractionated Heparin
Sponsor
Xiaobo Yang, MD